Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Express Scripts
Medtronic

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Navitoclax

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Navitoclax?

Navitoclax is an investigational drug.

There have been 15 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2011.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and Abbott.

There are one hundred and seventy-one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Navitoclax
TitleSponsorPhase
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative NeoplasmAbbViePhase 1
A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With MyelofibrosisAbbViePhase 2
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic LeukemiaAbbViePhase 1

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Navitoclax   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
Navitoclax   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
Navitoclax   Start Trial Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)   Start Trial
Navitoclax   Start Trial Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL)   Start Trial
Navitoclax   Start Trial Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders Novartis AG (Basel, CH)   Start Trial
Navitoclax   Start Trial N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 Novartis AG (Basel, CH)   Start Trial
Navitoclax   Start Trial Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases AbbVie Inc. (North Chicago, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Navitoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Navitoclax Canada 2922341 2033-08-28   Start Trial
Navitoclax European Patent Office 3038618 2033-08-28   Start Trial
Navitoclax World Intellectual Property Organization (WIPO) 2015031608 2033-08-28   Start Trial
Navitoclax Argentina 102649 2034-11-14   Start Trial
Navitoclax Australia 2015347015 2034-11-14   Start Trial
Navitoclax Brazil 112017009813 2034-11-14   Start Trial
Navitoclax Canada 2967188 2034-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Mallinckrodt
McKinsey
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.